1051375-16-6 | (3S,7R)-N-[(2,4-difluorophenyl)methyl]-11-hydroxy-7-methyl-9,12-dioxo-4-oxa-1,8-diazatricyclo[8.4.0.0^{3,8}]tetradeca-10,13-diene-13-carboxamide

Packsize	Purity	Availability	Price	Discounted Price
2mg	95%	in stock	$15.00	$10.00
5mg	95%	in stock	$18.00	$12.00
10mg	95%	in stock	$22.00	$15.00
50mg	95%	in stock	$33.00	$23.00
100mg	95%	in stock	$45.00	$31.00
250mg	95%	in stock	$66.00	$46.00
1g	95%	in stock	$114.00	$80.00
5g	95%	in stock	$291.00	$204.00
10g	95%	in stock	$441.00	$309.00
25g	95%	in stock	$869.00	$608.00

Description

• Catalog Number: AB52039
• Chemical Name: (3S,7R)-N-[(2,4-difluorophenyl)methyl]-11-hydroxy-7-methyl-9,12-dioxo-4-oxa-1,8-diazatricyclo[8.4.0.0^{3,8}]tetradeca-10,13-diene-13-carboxamide
• CAS Number: 1051375-16-6
• Molecular Formula: C20H19F2N3O5
• Molecular Weight: 419.3788
• MDL Number: MFCD20488027
• SMILES: Fc1ccc(c(c1)F)CNC(=O)c1cn2C[C@@H]3OCC[C@H](N3C(=O)c2c(c1=O)O)C

Computed Properties

• Complexity: 829
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 2
• Heavy Atom Count: 30
• Hydrogen Bond Acceptor Count: 8
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 3
• XLogP3: 2.4

Literature

• Antiviral Activity of Bictegravir and Cabotegravir against Integrase Inhibitor-Resistant SIVmac239 and HIV-1.

  Antimicrobial agents and chemotherapy 20171201

• Impact of HIV-1 Integrase L74F and V75I Mutations in a Clinical Isolate on Resistance to Second-Generation Integrase Strand Transfer Inhibitors.

  Antimicrobial agents and chemotherapy 20170801

• Antiviral characteristics of GSK1265744, an HIV integrase inhibitor dosed orally or by long-acting injection.

  Antimicrobial agents and chemotherapy 20150101

• Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir.

  Clinical pharmacokinetics 20131101

• Dolutegravir (Tivicay) for HIV.

  The Medical letter on drugs and therapeutics 20130930

• Dolutegravir: first global approval.

  Drugs 20130901

• Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.

  Lancet (London, England) 20130824

• Antiretroviral therapy: dolutegravir sets SAIL(ING).

  Lancet (London, England) 20130824

• Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness.

  Antimicrobial agents and chemotherapy 20130601

• In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.

  Drug metabolism and disposition: the biological fate of chemicals 20130201

• The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adults.

  Journal of acquired immune deficiency syndromes (1999) 20121101

• Prevalence of HIV-1 integrase mutations related to resistance to dolutegravir in raltegravir naïve and pretreated patients.

  Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 20121001

• The use of HIV-1 integrase inhibitors in antiretroviral naive patients.

  Current opinion in HIV and AIDS 20120901

• Pharmacology of HIV integrase inhibitors.

  Current opinion in HIV and AIDS 20120901

• HIV integrase inhibitors in ART-experienced patients.

  Current opinion in HIV and AIDS 20120901

• Tolerability of HIV integrase inhibitors.

  Current opinion in HIV and AIDS 20120901

• From in vitro EC₅₀ to in vivo dose-response for antiretrovirals using an HIV disease model. Part I: a framework.

  Journal of pharmacokinetics and pharmacodynamics 20120801

• Update on raltegravir and the development of new integrase strand transfer inhibitors.

  Southern medical journal 20120701

• Dolutegravir for the treatment of HIV.

  Expert opinion on investigational drugs 20120401

• Effect of a single supratherapeutic dose of dolutegravir on cardiac repolarization.

  Pharmacotherapy 20120401

• Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial.

  The Lancet. Infectious diseases 20120201

• Genetic barrier to the development of resistance to integrase inhibitors in HIV-1 subtypes CRF01_AE and B.

  Intervirology 20120101

• Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir.

  The Journal of infectious diseases 20111201

• Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572).

  Molecular pharmacology 20111001

• Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults.

  AIDS (London, England) 20110910

• Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S/GSK1349572.

  British journal of clinical pharmacology 20110701

• Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients.

  The Journal of antimicrobial chemotherapy 20110701

• Pharmacokinetics of the HIV integrase inhibitor S/GSK1349572 co-administered with acid-reducing agents and multivitamins in healthy volunteers.

  The Journal of antimicrobial chemotherapy 20110701

• S/GSK1349572, a new integrase inhibitor for the treatment of HIV: promises and challenges.

  Expert opinion on investigational drugs 20110401

• Implications of integrase inhibitors for HIV-infected transplantation recipients: raltegravir and dolutegravir (S/GSK 1349572).

  Bioscience trends 20110101

• Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers.

  Antimicrobial agents and chemotherapy 20100101